SCHEMBL3908212

SCHEMBL3908212

COc1cccc(N2C(=O)/C(=C/c3ccc(C)o3)SC2=S)c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 10/20 0.66
▸ KMT2A Q03164 10/20 0.66
▸ MAPT P10636 9/20 0.66
▸ RECQL P46063 3/20 0.66
▸ KDM4E B2RXH2 3/20 0.66
▸ MAPK1 P28482 3/20 0.66
▸ TDP1 Q9NUW8 1/20 0.66
▸ POLB P06746 7/20 0.62
▸ GAA P10253 2/20 0.62
▸ DUSP22 Q9NRW4 2/20 0.54
▸ MAP3K5 Q99683 1/20 0.52
▸ ALDH1A1 P00352 5/20 0.52
▸ ALOX12 P18054 3/20 0.52
▸ LMNA P02545 2/20 0.52
▸ MCL1 Q07820 1/20 0.52
▸ RAB9A P51151 2/20 0.48
▸ HPGD P15428 2/20 0.48
▸ L3MBTL1 Q9Y468 3/20 0.48
▸ THRB P10828 1/20 0.48
▸ CFTR P13569 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6275007 1.00 MEN1 (0.66) MEN1KMT2AMAPTRECQLKDM4E
SCHEMBL3908215 1.00 MEN1 (0.66) MEN1KMT2AMAPTRECQLKDM4E
SCHEMBL3892547 0.83 MEN1 (0.71) MEN1KMT2AMAPTRECQLKDM4E
SCHEMBL3892542 0.83 MEN1 (0.71) MEN1KMT2AMAPTRECQLKDM4E
SCHEMBL3895721 0.83 CFTR (0.63) MEN1KMT2AMAPTRECQLKDM4E
SCHEMBL3895716 0.83 CFTR (0.63) MEN1KMT2AMAPTRECQLKDM4E
SCHEMBL3890772 0.82 KMT2A (0.64) MEN1KMT2AMAPTRECQLKDM4E
SCHEMBL3890778 0.82 KMT2A (0.64) MEN1KMT2AMAPTRECQLKDM4E
SCHEMBL3897777 0.78 MEN1 (0.65) MEN1KMT2AMAPTRECQLKDM4E
SCHEMBL3897872 0.78 MAPT (0.65) MEN1KMT2AMAPTRECQLKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US claimed
US-7566732-B2 Rhodanine compositions for use as antiviral agents RIGEL PHARMACEUTICALS, INC. (US) 2009-07-28 — — US disclosed
US-7566732-B2 Rhodanine compositions for use as antiviral agents RIGEL PHARMACEUTICALS, INC. (US) 2009-07-28 — — US disclosed
US-7566732-B2 Rhodanine compositions for use as antiviral agents RIGEL PHARMACEUTICALS, INC. (US) 2009-07-28 — — US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US disclosed
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RIGEL PHARMACEUTICALS, INC. (US) 2009-05-28 — — US disclosed
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them RIGEL PHARMACEUTICALS, INC. (US) 2006-12-07 — — US disclosed
WO-2004043955-A1 RHODANINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM RIGEL PHARMACEUTICALS, INC. (US) 2004-05-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276520-A1 Rhodanine derivatives and pharmaceutical compositions containing them UBQLN1, UBQLN2, UBE2G2 MEN1 1562/4885KMT2A 901/4885MAPT 1187/4885
US-20090137644-A1 RHODANINE COMPOSITIONS FOR USE AS ANTIVIRAL AGENTS RBX1, ITCH, UBQLN1 MEN1 2869/4885KMT2A 1020/4885MAPT 880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback